Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that BCR::ABL1 status confers therapeutic sensitivity to Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Vincristine in patients with Acute Lymphoid Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved UKALL14 phase 1 standard induction therapy as a treatment option for the induction of remission in newly diagnosed, previously untreated adult patients with acute lymphoblastic leukaemia (ALL) patients (aged 25-65 years) treated on UKALL14-protocol. The treatment regimen notes that this is a clinical trial protocol intended for off-trial use, and that rituximab is to be included in CD20 positive patients (defined as >20% positivity). The treatment regimen also defines eligibility criteria as aged >= 25 and <= 65. years old with acute lymphoblastic leukaemia OR >= 19 and <= 65 years old with Philadelphia Chromosome Positive acute lymphoblastic leukaemia. Core treatments constituting the regimen are dexamethasone, daunorubicin, vincristine, and methotrexate, with rituximab to be included for CD20 positive patients, imatinib to be included for Philadelphia chromosome positive patients, or PEG-asparaginase for philadelphia chromosome negative patients.
This statement is based on a regulatory approval from the Health Service Executive:
Induction of remission in newly diagnosed, previously untreated adult acute lymphoblastic leukaemia (ALL) patients (aged 25-65 years) treated on UKALL14-protocol.